Tovecimig

A4DAB274 | Cancer | Phase-II/III
VEGFA
G1;non-canonical / TBD
ABL Bio Compass Therapeutics Elpiscience Biopharmaceuticals National OncoVenture University of Texas M. D. Anderson Cancer Center TRIGR Therapeutics
Phase-II/III
Bispecific Mixed mAb and scFv
ABL-001 ABL 001 ABL001 CTX-009 CTX 009 CTX009 ES 104 ES-104 ES104 HD-B001A NOV1501 NOV-1501 NOV 1501 TR-009 TR 009 TR009
—
IMGT PubChem (507428328) PubChem (520378463) Thera-SAbDab YAbS
Avg A4D Score
-0.6784
Score Range
-0.71 to -0.64
Structures
8
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB274_7v5n_B_A 7v5n 100% -0.6788 6.5 4.0 -0.3101 -0.7267
A4DAB274_1bj1_K_J 1bj1 100% -0.6424 6.5 4.0 -0.171 -0.7042
A4DAB274_7v5n_F_E 7v5n 100% -0.6761 6.5 4.0 -0.2723 -0.7296
A4DAB274_6bft_H_L 6bft 98% -0.7047 6.5 4.0 -0.3845 -0.7469
A4DAB274_6bft_A_B 6bft 98% -0.713 6.5 4.0 -0.3946 -0.754
A4DAB274_1cz8_Y_X 1cz8 97% -0.6636 6.5 4.0 -0.0974 -0.7379
A4DAB274_1bj1_H_L 1bj1 100% -0.6886 6.5 4.0 -0.1696 -0.7567
A4DAB274_1cz8_H_L 1cz8 97% -0.6603 6.5 4.0 -0.0949 -0.7345